Last updated: February 19, 2026
This report provides a detailed analysis of European Patent EP3045175, covering its claimed subject matter, protective scope, and its position within the broader pharmaceutical patent landscape. The patent, assigned to Bristol-Myers Squibb Company, claims pharmaceutical compositions containing nivolumab, a human immunoglobulin G4 (IgG4) monoclonal antibody.
What Subject Matter Does EP3045175 Claim?
EP3045175 claims pharmaceutical compositions and methods of use related to nivolumab. The patent's core claims are directed towards specific formulations of nivolumab designed for therapeutic administration.
Key Claimed Subject Matter:
- Claim 1: A pharmaceutical composition comprising: a) a therapeutically effective amount of an antibody, wherein the antibody is nivolumab; and b) a pharmaceutically acceptable carrier. The antibody is further characterized by specific binding to PD-1.
- Claim 2: The pharmaceutical composition of claim 1, wherein the antibody is a human IgG4 antibody.
- Claim 3: The pharmaceutical composition of claim 1 or 2, wherein the antibody comprises specific amino acid sequences for its variable heavy (VH) and variable light (VL) domains, as detailed in the patent.
- Claim 4: The pharmaceutical composition of any preceding claim, wherein the antibody comprises specific CDR (Complementarity-Determining Region) sequences that define its antigen-binding site.
- Claim 5: A method of treating cancer in a subject, comprising administering a therapeutically effective amount of the pharmaceutical composition of any preceding claim.
- Claim 6: The method of claim 5, wherein the cancer is selected from melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma, or urothelial carcinoma.
- Claim 7: The method of claim 5 or 6, wherein the subject has previously been treated with one or more agents for the cancer.
The claims define nivolumab based on its binding to the Programmed Cell Death protein 1 (PD-1) receptor and its specific amino acid sequence, particularly within the variable regions responsible for antigen binding. The patent also covers methods of using these compositions for treating various cancers.
What Is the Protective Scope of EP3045175?
The protective scope of EP3045175 extends to pharmaceutical formulations of nivolumab and its use in treating specific oncological indications. The patent's claims are broad enough to cover various carriers and formulations, provided they contain the defined nivolumab antibody.
Aspects of Protective Scope:
- Product Claims: The patent protects the specific pharmaceutical composition containing nivolumab. This means any entity manufacturing or selling a composition that meets the criteria of claim 1, including the specified antibody characteristics, without authorization, infringes.
- Method of Treatment Claims: The patent also claims methods of treating specific cancers using the nivolumab composition. This scope can impact diagnostic or therapeutic services that administer the patented composition.
- Antibody Characterization: The claims are anchored by detailed characterization of the nivolumab antibody, including its binding affinity to PD-1 and specific amino acid sequences. This precision limits the scope to nivolumab and closely related variants that possess the same essential binding characteristics and sequence homology.
- Formulation Neutrality: While claim 1 specifies a "pharmaceutically acceptable carrier," the claims do not restrict the invention to a single, specific formulation (e.g., a particular buffer composition or excipient profile) unless further sub-claims introduce such limitations. This offers broad protection for various delivery systems.
- Therapeutic Indications: The patent covers the treatment of a defined list of cancers, including melanoma, NSCLC, renal cell carcinoma, and urothelial carcinoma. This scope is significant as it covers established and potential indications for nivolumab therapy.
The European Patent Office (EPO) granted EP3045175, signifying that, in their assessment, the invention meets the criteria for patentability, including novelty, inventive step, and industrial applicability. The patent's validity can be challenged through opposition proceedings at the EPO or invalidity actions in national courts within member states.
What Is the Patent Landscape for EP3045175?
EP3045175 is situated within a competitive landscape of patents covering immune checkpoint inhibitors, particularly those targeting the PD-1/PD-L1 axis. Bristol-Myers Squibb (BMS) is a major player in this field with Opdivo® (nivolumab) being a flagship product.
Key Elements of the Patent Landscape:
- Dominant Player (Bristol-Myers Squibb): BMS holds a significant portfolio of patents related to nivolumab, including those covering its composition, manufacturing, and therapeutic applications. EP3045175 is one component of this broader intellectual property strategy.
- Competitors: Other pharmaceutical companies, including Merck & Co. (pembrolizumab, Keytruda®), Roche (atezolizumab), and AstraZeneca (durvalumab), also hold extensive patent portfolios covering their respective PD-1 or PD-L1 inhibitors. These patents often claim different antibodies, specific formulations, manufacturing processes, or novel therapeutic uses.
- Patent Families: EP3045175 is part of a larger patent family, indicating that BMS has sought protection for nivolumab and related technologies in multiple jurisdictions worldwide. This global filing strategy is typical for blockbuster drugs.
- Evergreening Strategies: The patent landscape for successful drugs often includes "evergreening" strategies, where patent holders seek new patents on incremental innovations such as new formulations, dosing regimens, or combination therapies. EP3045175, by claiming pharmaceutical compositions and methods of use, can be considered part of such a strategy, potentially extending market exclusivity beyond the initial composition of matter patents.
- Patent Expiry: The lifespan of a European patent is 20 years from the filing date. EP3045175, filed in 2015, is expected to expire in 2035, assuming it maintains its validity. However, Supplementary Protection Certificates (SPCs) can extend the effective market exclusivity for medicinal products in Europe for up to five additional years.
- Litigation and Licensing: The immune checkpoint inhibitor market is a high-value area, leading to significant patent litigation and licensing activities. Companies often defend their patents aggressively and may enter into cross-licensing agreements to navigate complex IP landscapes.
The existence of EP3045175, alongside patents from competitors, shapes the commercialization and generic entry timelines for nivolumab and similar therapies. Companies seeking to enter the market with biosimilar versions of nivolumab would need to carefully analyze EP3045175 and its patent family to identify potential infringement risks and pathways for market entry.
What Are the Implications of EP3045175 for Market Entry?
EP3045175 imposes restrictions on third parties seeking to market pharmaceutical compositions containing nivolumab or utilize such compositions for the treatment of specific cancers within the European patent territories covered by this patent.
Market Entry Implications:
- Composition of Matter & Formulation Protection: The patent claims cover the pharmaceutical composition itself. Any product marketed as nivolumab in a pharmaceutically acceptable carrier, meeting the antibody's characterization in the claims, infringes upon EP3045175 until its expiry or invalidation.
- Method of Treatment Restrictions: The claims related to methods of treating specific cancers mean that even if a third party develops a non-infringing nivolumab composition, they may still infringe if their product is promoted or used for the patented indications.
- Biosimilar Development: For companies developing biosimilar versions of nivolumab, EP3045175 represents a critical hurdle. A biosimilar must demonstrate high similarity to the reference product (Opdivo®) but must not infringe on valid patents. This typically involves developing a composition that is either structurally distinct in a way that avoids claim scope or challenging the validity of EP3045175 and its associated patent family.
- Geographic Scope: European patents are national rights validated in individual member states. Infringement analysis and enforcement must be conducted on a country-by-country basis for the specific states where the patent has been validated.
- Patent Cliff: The expiry of EP3045175 (potentially extended by SPCs) will mark a "patent cliff," creating opportunities for generic or biosimilar manufacturers to enter the market without facing direct infringement risk from this specific patent.
Understanding the precise wording of the claims in EP3045175 and its claims history, including any amendments made during prosecution, is essential for accurately assessing infringement risks and planning market entry strategies.
How Does EP3045175 Compare to Other PD-1 Inhibitor Patents?
EP3045175, claiming nivolumab compositions and methods, occupies a specific niche within the broader patent landscape of PD-1 and PD-L1 inhibitors. While all these patents aim to protect commercially valuable immunotherapies, their scope and focus differ.
Comparative Analysis:
- Specificity of Antibody: EP3045175 protects a specific antibody, nivolumab. Patents for other PD-1 inhibitors, such as Merck's pembrolizumab (Keytruda®), claim different antibodies with distinct amino acid sequences, even though they target the same PD-1 receptor. This means EP3045175 does not inherently block the sale of pembrolizumab.
- Claim Type: EP3045175 includes claims for the pharmaceutical composition and methods of treatment. Some patents in the field may focus more narrowly on the antibody's sequence (composition of matter), manufacturing processes, specific salt forms, or novel combination therapies. For example, some patents might claim nivolumab in combination with specific chemotherapies or other immune modulators.
- Breadth of Formulation Claims: While EP3045175 claims compositions, its breadth regarding specific formulations is a key point of comparison. If other patents claim highly specific and novel formulations of PD-1 inhibitors (e.g., long-acting injectables, specific adjuvant combinations), they would represent distinct protective layers.
- Target Indications: The indications claimed in EP3045175 (melanoma, NSCLC, renal cell carcinoma, urothelial carcinoma) are significant but may not encompass all potential uses of PD-1 inhibitors. Other patents may claim broader sets of cancers or specific patient populations identified through biomarkers.
- Filing Strategy: EP3045175 is part of BMS's global IP strategy for nivolumab. Competitors have similar strategies for their respective drugs. The interplay between these diverse patent families, each with its own scope and expiry dates, creates a complex web of intellectual property that influences market dynamics and R&D decisions.
In essence, EP3045175 protects a specific iteration of a PD-1 inhibitor. While it is a strong patent for nivolumab, it does not grant exclusivity over the entire PD-1 inhibitor class. Competitors' patents cover different antibodies, formulations, or uses, creating a landscape where patent challenges, licensing, and careful freedom-to-operate analyses are paramount.
What Are the Key Risks Associated with EP3045175?
EP3045175 presents several risks for third parties operating within the oncology therapeutic space, particularly those involved in developing or manufacturing immune checkpoint inhibitors.
Key Risks:
- Infringement of Composition Claims: Any entity producing or marketing a pharmaceutical composition containing nivolumab that falls within the scope of EP3045175’s claims risks direct infringement. This includes manufacturers of biosimilar nivolumab.
- Infringement of Method of Treatment Claims: Utilizing the patented composition for the treatment of the specified cancers, even if the composition itself is developed through non-infringing means, can lead to method of treatment infringement.
- Cost of Litigation: Defending against patent infringement claims can be extremely costly and time-consuming, involving extensive legal fees, expert witness testimonies, and potential damages.
- Market Access Delays: Facing patent litigation can lead to injunctions that prevent market entry or continued sales, significantly delaying commercialization and revenue generation.
- Invalidity Challenges: While EP3045175 is presumed valid upon grant, it can be challenged through opposition or invalidity proceedings. However, successfully invalidating a patent requires substantial evidence and legal arguments, which itself is a resource-intensive undertaking.
- Freedom to Operate Uncertainty: The existence of EP3045175, as part of a larger patent portfolio, contributes to the overall complexity of obtaining freedom to operate in the PD-1 inhibitor market. Generic and biosimilar developers must conduct thorough freedom-to-operate analyses covering all relevant patents.
These risks necessitate a proactive and comprehensive approach to intellectual property assessment, including detailed claim analysis, patent landscape mapping, and strategic legal counsel.
Key Takeaways
European Patent EP3045175 claims pharmaceutical compositions containing nivolumab and methods for treating specific cancers. The patent is held by Bristol-Myers Squibb and is a critical piece of intellectual property protecting its blockbuster immunotherapy, Opdivo®. The claims are characterized by the specific antibody sequences and binding properties of nivolumab, and they cover its use in treating melanoma, non-small cell lung cancer, renal cell carcinoma, and urothelial carcinoma. The patent's scope provides significant market exclusivity, posing infringement risks for third parties, particularly those developing biosimilar versions of nivolumab. Its expiry, expected in 2035 with potential SPC extensions, will influence the timing of generic market entry. The competitive landscape for PD-1 inhibitors is dense with patents from multiple companies, necessitating careful freedom-to-operate analyses for any new market entrant.
Frequently Asked Questions
-
What is the specific chemical entity protected by EP3045175?
EP3045175 protects pharmaceutical compositions containing nivolumab, a human immunoglobulin G4 monoclonal antibody that binds to PD-1. The claims define the antibody by its antigen-binding characteristics and specific amino acid sequences within its variable regions.
-
Does EP3045175 prevent the sale of any PD-1 inhibitor?
No, EP3045175 specifically protects compositions and methods involving nivolumab. It does not prevent the sale of other PD-1 or PD-L1 inhibitors, such as pembrolizumab or atezolizumab, as these are different chemical entities, though they target the same biological pathway.
-
When does EP3045175 expire?
The European Patent EP3045175 was filed in 2015 and has a standard term of 20 years from the filing date. Therefore, it is expected to expire in 2035. This term can be extended in European countries via Supplementary Protection Certificates (SPCs) for medicinal products.
-
What are the implications for biosimilar manufacturers seeking to market nivolumab?
Biosimilar manufacturers must ensure their product does not infringe on the claims of EP3045175 and its associated patent family. This may involve demonstrating sufficient structural and functional similarity while avoiding claimed formulations or methods, or challenging the validity of the patent.
-
Can EP3045175 be challenged?
Yes, European patents can be challenged. Following grant, any third party can file an opposition with the European Patent Office within nine months. After this period, or if opposition proceedings conclude, invalidity actions can be pursued in the national courts of the designated European countries where the patent has been validated.
Citations
[1] Bristol-Myers Squibb Company. (2016). EP3045175 B1: Pharmaceutical composition for treating cancer. European Patent Office. Retrieved from [EPO Official Register or Espacenet database] (Specific URL depends on access to EPO database).
